Bayer's investigational PET tracer shows high accuracy for cardiac amyloidosis

August 31, 2026 - 10:58

New data presented at the European Society of Cardiology Congress suggests that an investigational PET imaging agent from Bayer could significantly improve the diagnosis of a debilitating heart condition. The tracer, designed to bind to amyloid deposits in the heart, demonstrated high diagnostic accuracy in identifying patients with cardiac amyloidosis, a disease often referred to as stiff heart syndrome.

The condition occurs when abnormal proteins build up in the heart muscle, making it rigid and impairing its ability to pump blood effectively. Historically, diagnosis has been challenging, often requiring invasive biopsies or relying on less specific imaging methods. The new findings indicate that the PET tracer can non-invasively detect the presence and extent of amyloid buildup with remarkable precision, potentially allowing for earlier intervention and better management of the disease.

Researchers presented the data during a late-breaking session at the annual cardiology meeting, highlighting the tracer's potential to become a standard tool in the diagnostic workup. If approved, the agent would offer a more accessible and accurate alternative to current techniques, which often miss the disease in its early stages. The results are considered a significant step forward, as timely diagnosis is critical for initiating treatments that can slow disease progression and improve patient outcomes. Further clinical trials will be necessary to confirm the findings and secure regulatory approval.